Meropenem-Vaborbactam: Who Benefits From Vabomere?

Why does pandemic-era resistance matter for antibiotic treatment?

The CDC's COVID-19 and antimicrobial resistance overview describes a reversal in progress during the pandemic. Across seven pathogens, hospital-onset resistant infections and associated deaths each increased by at least 15% between 2019 and 2020. Longer admissions, greater use of invasive devices and disruption to infection prevention contributed to the challenge. These are historical surveillance findings, not newly measured infection rates for October 2026. [CDC overview](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

One treatment challenge involves Enterobacterales that produce KPC, an enzyme capable of breaking down carbapenem antibiotics. Meropenem-vaborbactam combines an antibiotic that disrupts bacterial cell-wall construction with an inhibitor that protects it against certain bacterial enzymes. That protection can restore activity against susceptible KPC-producing bacteria. The drug's effectiveness therefore depends on the organism's defenses, rather than simply whether an infection is described as resistant. [Vabomere prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e237fd0f-3050-42a3-b43e-b6fb4824e93d).

What did the TANGO II trial show about meropenem-vaborbactam?

The TANGO II trial, published in 2018, randomized 77 adults with suspected or confirmed carbapenem-resistant Enterobacterales infections. Its principal analysis included 47 participants with confirmed infections. At the end of treatment, clinical cure occurred in 21 of 32 patients receiving meropenem-vaborbactam, compared with five of 15 receiving best available therapy: approximately 66% versus 33%. The comparator consisted of treatments selected by investigators, rather than one standardized antibiotic regimen. [TANGO II trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC6249182/).

The result supported the combination's clinical usefulness, but its precision and generalizability have limits. The study was open-label, included several infection types and was funded by The Medicines Company. Mortality was numerically lower with meropenem-vaborbactam, but the difference was not statistically conclusive. These findings cannot establish superiority over every newer antibiotic or reliably predict outcomes for each infection site. [TANGO II results and disclosures](https://pmc.ncbi.nlm.nih.gov/articles/PMC6249182/).

Who can receive Vabomere, and what determines whether it will work?

Vabomere's US indication covers complicated urinary tract infections, including kidney infections, caused by designated susceptible bacteria in adults. IDSA's July 2026 guidance also identifies meropenem-vaborbactam as a preferred treatment for invasive KPC-producing Enterobacterales infections; some such uses fall outside the US labeled indication. Vaborbactam does not block NDM, another important resistance enzyme, so this combination cannot be assumed to treat every carbapenem-resistant infection. [US prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e237fd0f-3050-42a3-b43e-b6fb4824e93d), [IDSA guidance](https://www.idsociety.org/practice-guideline/amr-guidance).

The medicine is administered intravenously, with dose adjustment for impaired kidney function. Clinicians must review allergy history and interacting medicines. Important risks include severe allergic reactions, seizures and C. difficile-associated diarrhea. Meropenem can substantially lower valproate concentrations, potentially compromising seizure control. These considerations make treatment selection and monitoring essential even when laboratory results suggest the bacteria are susceptible. [Vabomere safety information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e237fd0f-3050-42a3-b43e-b6fb4824e93d).